Mithra Pharmaceuticals SA announced they have signed a binding supply agreement for the active pharmaceutical ingredient (API) for the combined oral contraceptive Estelle and Donesta, a novel product candidate for the treatment of post-menopausal symptoms. The agreement specifies that Gedeon Richter will manufacture and supply the Estetrol (E4) native estrogen for Mithra?s Estelle® and Donesta®. Gedeon Richter will manufacture and supply Estetrol (E4) for production of Estelle®, Donesta® Strengthens Mithra?ssupplychainwith commercially attractive source for Estetrol .
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.216 EUR | -1.82% | -.--% | -82.78% |
May. 28 | Mithra Delays AGM Amid Monetization Process | MT |
Apr. 29 | Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-82.78% | 16.25M | |
-1.62% | 90.85B | |
-0.92% | 39.02B | |
-10.22% | 33.46B | |
-18.41% | 14.51B | |
-5.93% | 13.22B | |
-9.76% | 11.65B | |
-47.31% | 10.57B | |
+6.52% | 9.23B | |
+137.06% | 7.71B |
- Stock Market
- Equities
- MITRA Stock
- News Mithra Pharmaceuticals S.A.
- Mithra Pharmaceuticals SA and Gedeon Richter Sign Supply Agreement for Production of API for Estelle and Donesta